High-Dose Rosuvastatin Preloading for Enhanced Outcomes in STEMI Patients Undergoing Primary PCI (HEROS-PCI)

Sheikh Zayed Federal Postgraduate Medical Institute

Status and phase: Active, not recruiting; Phase 2

Conditions: ST Elevation (STEMI) Myocardial Infarction

Treatments: Drug: Placebo; Drug: Statin monotherapy (rosuvastatin or atorvastatin)

Study type: Interventional

Funder types: Other

Identifiers

NCT06924684

UHS/IRB/0156/2024

Details and patient eligibility

About

To compare the efficacy of high dose rosuvastatin preloading vs placebo before primary PCI in terms of MACE at 30 days

Enrollment: 66 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 18-75 years Patients undergoing primary angiography

Exclusion criteria

• Hemodynamically unstable patients. History or clinical evidence of any co-morbidities. Taking any medications regularly even statins.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

66 participants in 2 patient groups, including a placebo group

Intervention arm

Active Comparator group

Description:

Tab Rosuvastatin 40mg at presentation. Tab Rosuvastatin 20mg at night for 30 days.

Treatment:

Drug: Statin monotherapy (rosuvastatin or atorvastatin)

Placebo Arm

Placebo Comparator group

Description:

Placebo capsule 40mg (weight) at presentation. Tab Rosuvastatin 20mg at night for 30 days.

Treatment:

Drug: Placebo